NEW YORK, Nov. 11, 2014 /PRNewswire/ -- As testosterone lawsuits (http://www.testosteronelawsuithub.com/) continue to be filed in U.S. courts on behalf of men who allegedly suffered serious heart problems due to their use of AndroGel and similar medications, Bernstein Liebhard LLP notes a new report suggesting that the safety concerns surrounding the drugs may be causing sales to slow. According to Bloomberg Businessweek, sales of AndroGel dropped 5% in the first half of 2014, while sales of the entire class of medications fell 6%.
The decline followed the U.S. Food & Drug Administration's (FDA) announcement in January that it was looking into the cardiovascular side effects that may be associated with low testosterone therapy. Spending on advertising for low testosterone therapy is also down this year, which may reflect growing concerns over how the drugs are marketed, according to Bloomberg Businessweek.
"Since the FDA launched its safety review, our Firm has heard from numerous men who allegedly suffered heart attacks and other cardiovascular problems due to their use of low testosterone therapy. It would not be at all surprising if the concerns surrounding these medications were beginning to impact their sales," says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free and confidential case reviews to individuals who may have suffered heart attacks, strokes, deep vein thrombosis or pulmonary embolism due to their use of testosterone treatment therapies.
Testosterone Treatment Lawsuits
The FDA began investigating low testosterone therapies after two studies indicated they may increase the risk of heart attacks, strokes and death in certain men. One study, which was published last November in the Journal of the American Medical System, reported an increased risk of heart attack, stroke and death among older men with pre-existing heart problems. The second study, which appeared in PLOS One in January, suggested that such treatments ware associated with a doubling of the heart attack risk among younger men with pre-existing heart problems, and in men over 65 regardless of their heart health.
In September, a panel of outside advisors convened by the FDA recommended that the manufacturers of the medications be required to conduct studies of their cardiovascular side effects. The advisors also recommended that the labeling for low testosterone therapies be revised to make clear they have not been shown to lessen symptoms commonly experienced by aging men.
According to court documents, more than 220 testosterone treatment lawsuits have been filed in a federal litigation underway in the U.S. District Court, Northern District of Illinois, all of which allege that the use of drugs like AndroGel increases a patient's risk for life-threatening cardiovascular events, including heart attacks, strokes and blood clots. The lawsuits further allege that the manufacturers of testosterone therapies engaged in aggressive marketing that encouraged men without any real medical need to seek treatment for low sex drive, fatigue and other symptoms merely associated with aging. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)
Men who used prescription testosterone treatments may be entitled to compensation if they suffered strokes, heart attacks, deep vein thrombosis, pulmonary embolism or another serious cardiovascular event while using these medications. To learn more about filing a testosterone lawsuit, please visit Bernstein Liebhard LLP's website. Free, no-obligation legal consultations can be obtained by calling (888) 340-4807.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
SOURCE Bernstein Liebhard LLP